Seeking Alpha

Celgene (CELG +0.9%) finishes the day in the positive after U.S. regulators approved its...

Celgene (CELG +0.9%) finishes the day in the positive after U.S. regulators approved its Abraxana medication, a first-line treatment of advanced non-small cell lung cancer in patients not being treated surgically or with radiation therapy.
Comments (1)
  • HarryKlari
    , contributor
    Comments (2) | Send Message
     
    This is a Billion dollar drug...then comes pancreatic cancer and melanoma and other indications. Looks like today's bright lights bought on the rumor and sold on the news. made pennies. lost opportunities for real wealth. Celg is a screaming bargain IMHO
    12 Oct 2012, 07:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector